Florin A. Caruntu
Bucharest, B, Romania
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
From Diagnosis to Durability: A Review of the European Bulevirtide Experience and Practical Learnings for CHD Management.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: March 06, 2026
Ten-Year Follow-Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT-II): Improved Clinical Outcome After Combination Therapy.
Journal: United European gastroenterology journal
Published: October 21, 2025
Frequency, Severity and Impact of Pegylated Interferon Alpha-Associated Flares in Hepatitis D Infection.
Journal: Journal of viral hepatitis
Published: June 03, 2024
Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: April 23, 2023
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.
Journal: The American journal of gastroenterology
Published: February 10, 2023
Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: December 16, 2022
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: June 22, 2020
A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction.
Journal: Journal of viral hepatitis
Published: April 30, 2020
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: March 11, 2020
Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.
Journal: Digestive diseases and sciences
Published: October 17, 2018
Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis.
Journal: Digestive diseases and sciences
Published: May 15, 2018
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
Journal: The Lancet. Infectious diseases
Published: April 26, 2018
Last Updated: 09/26/2026